Provided by Tiger Fintech (Singapore) Pte. Ltd.

Palisade Bio Inc.

1.00
+0.08258.99%
Post-market: 0.9350-0.0650-6.50%19:57 EDT
Volume:1.46M
Turnover:1.48M
Market Cap:2.77M
PE:-0.07
High:1.10
Open:0.9600
Low:0.9536
Close:0.9175
Loading ...

Palisade Bio Inc - Topline Data Expected in First Half of 2025

THOMSON REUTERS
·
03 Dec 2024

Palisade Bio Announces Preliminary Data From Phase 1 Clinical Study of Pali-2108 for the Treatment of Moderate-to-Severe Ulcerative Colitis Appears to Be Safe and Well Tolerated in Treated Subjects

THOMSON REUTERS
·
03 Dec 2024

Palisade Bio Announces Preliminary Data from Phase 1 Clinical Study of PALI-2108 for the Treatment of Moderate-to-Severe Ulcerative Colitis Appears to be Safe and Well Tolerated in Treated Subjects

GlobeNewswire
·
03 Dec 2024

BRIEF-Palisade Bio Inc - Offering 2.1 Million Shares At $2.43 Per Share

Reuters
·
22 Nov 2024

Palisade Bio Inc - Offering 2.1 Mln Shares at $2.43 per Share

THOMSON REUTERS
·
22 Nov 2024

Palisade Bio to Present Preclinical Results for PALI-2108 Demonstrating Engagement of Key Fibrotic Pathways of Crohn's Disease and Ulcerative Colitis (UC)

GlobeNewswire
·
21 Nov 2024

Palisade Bio Initiated at Buy by Brookline Capital

Dow Jones
·
21 Nov 2024

Palisade Bio initiated with a Buy at Brookline

TIPRANKS
·
21 Nov 2024

Palisade Bio Is Maintained at Buy by Maxim Group

Dow Jones
·
14 Nov 2024

U.S. RESEARCH ROUNDUP- AMN Healthcare Services, Chart Industries, Home Depot

Reuters
·
13 Nov 2024

Palisade Bio Inc : Maxim Group Cuts Target Price to $8 From $22.50

THOMSON REUTERS
·
13 Nov 2024

Palisade Bio Q3 EPS $(2.32) Beats $(3.35) Estimate

Benzinga
·
12 Nov 2024

Palisade Bio Reports Third Quarter 2024 Financial Results and Outlines Key Accomplishments and Next Steps to Advance Lead Program Pali-2108

THOMSON REUTERS
·
12 Nov 2024

Palisade Bio Inc: Qtrly Net Loss per Share $2.32

THOMSON REUTERS
·
12 Nov 2024

Palisade Bio Reports Third Quarter 2024 Financial Results and Outlines Key Accomplishments and Next Steps to Advance Lead Program PALI-2108

GlobeNewswire
·
12 Nov 2024

BRIEF-Palisade Bio Announces First Subject Dosed In Phase 1 Clinical Study Of Pali-2108 For The Treatment Of Moderate-To-Severe Ulcerative Colitis

Reuters
·
07 Nov 2024